Compare J M Smucker Co (SJM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J M Smucker Co vs State Street SPDR S&P Biotech ETF — how do they compare? J M Smucker Co trades at $123.58 (market cap $13.32B), while State Street SPDR S&P Biotech ETF trades at $159.93. The key difference: J M Smucker Co pays a 3.59% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| SJM | XBI | |
|---|---|---|
Market Cap | $13.32B | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $132.34 | $169.55 |
52-Week Low | $89.53 | $93.43 |
Enterprise Value | $20.17B | — |
Dividend Yield | 3.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SJM trades at $124.66, down 1.13% on the day, with a bullish technical signal per moving averages despite oscillators showing bearish momentum. The company reported strong Q1 2027 earnings, beating estimates with EPS of $3.24, and raised full-year guidance. Valuation metrics include a P/E of 58.25 and P/S of 1.45, while recent news highlights CEO and CFO stock sales and positive analyst sentiment.
Outlook is positive with a consensus price target of $144.78, implying 16% upside, supported by earnings momentum and dividend yield. Risks include high debt levels, with debt-to-asset ratio at 43.71% in 2025, and volatile net income margins, which turned negative in 2025. Investors should weigh strong recent performance against financial leverage and insider selling activity.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
